Assessment of C-reactive protein and C3 as inflammatory markers of insulin resistance in women with polycystic ovary syndrome: A case-control study

Journal of Reproduction and Infertility

Volumn 14, Issue 4, 2013, Pages 197-201

  Dehdashtihaghighat, Setareh ^a   Mehdizadehkashi, Abolfazl ^a   Arbabi, Amirmohsen ^b   Pishgahroudsari, Mohadeseh ^a   Chaichian, Shahla ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C reactive protein; C3; Insulin resistance; Polycystic ovary syndrome

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PATIENT ASSESSMENT; POSTPRANDIAL STATE;

EID: 84890416109     PISSN: 22285482     EISSN: 2251676X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Evian Annual Reproduction (EVAR) Workshop Group 2010, Fauser BC, Diedrich K, Bouchard P, Dominguez F, Matzuk M, et al. Contemporary genetic technologies and female reproduction. Hum Reprod Update. 2011;17(6):829-47.
2. Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril. 2003;80(2):255-8.
3. Oktenli C, Ozgurtas T, Dede M, Sanisoglu YS, Yenen MC, Yesilova Z, et al. Metformin decreases circulating acylation-stimulating protein levels in polycystic ovary syndrome. Gynecol Endocrinol. 2007;23(12):710-5.
4. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9.
5. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006;21(6):1426-31.
6. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141-6.
7. Muscari A, Antonelli S, Bianchi G, Cavrini G, Dapporto S, Ligabue A, et al. Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care. 2007;30(9):2362-8.
8. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972-8.
9. Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D, et al. C reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract. 2006;71(1):92-100.
10. Ford ES. Body mass index, diabetes, and C reactive protein among U.S. adults. Diabetes Care. 1999;22(12):1971-7.
11. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23(12):1835-9.
12. Ridker PM, Buring JE, Cook NR, Rifai N. C reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391-7.
13. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older nondiabetic men. Atherosclerosis. 2005;181(1):101-8.
14. Yang S, Li Q, Song Y, Tian B, Cheng Q, Qing H, et al. Serum complement C3 has a stronger association with insulin resistance than high-sensitivity C-reactive protein in women with polycystic ovary syndrome. Fertil Steril. 2011;95(5):1749-53.
15. Ravn P, Haugen AG, Glintborg D. Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. Minerva Endocrinol. 2013;38(1):59-76.
16. Tosi F, Dorizzi R, Castello R, Maffeis C, Spiazzi G, Zoppini G, et al. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. Eur J Endocrinol. 2009;161(5):737-45.
17. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293(6543):355-9.
18. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf). 1996;44(3):277-84.
19. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-43.
20. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care. 2002;5(4):377-83.
21. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 2001;25(9):1327-31.